CTLA4 and melanoma: When combined with anti-CTLA-4 immune checkpoint blockade, MIF inhibition could overcome resistance to melanoma immune checkpoint blockade therapy by increasing CD8+ TIL (de Azevedo et al., 2020), which may release IFN γ to induce ferroptosis, thus promoting antitumor responses.